NPPA sets retail price for 15 key drug formulations and ceiling price for framycetin

The National Pharmaceutical Pricing Authority (NPPA), which falls under the Ministry of Chemicals and Fertilizers, has set the price of 15 key drug formulations, mainly used to treat diseases such as diabetes. Prices must now be respected by pharmaceutical companies. The ceiling price for framycetin, an antibiotic used to treat burns, was also notified.

The prices were set after a meeting held the last week of March, the NPPA order said.

The price of metformin (extended release) plus teneligliptin tablet, manufactured and marketed by Associated Biotech, Dales Laboratories, has been set at ₹7.14 per tablet. Similarly, the retail price of dapagliflozin plus metformin hydrochloride extended release tablet has been set at ₹10.7 per tablet.

Both tablets are used to treat diabetes.

The NPPA, it will be recalled, has the mandate to set or revise the price of bulk drugs and controlled formulations, as well as to enforce prices and ensure the availability of drugs in the country. It also monitors the prices of deregulated drugs.

Among other formulations, the retail price of human normal immunoglobulin for intravenous use, intended for the treatment of certain diseases caused by a lack of antibodies in the blood, has been set at ₹177.85 for a 10ml vial .

A single extended release tablet of medroxyprogesterone acetate – an ovulation regulating hormone – will cost ₹14.04.

According to the NPPA, manufacturers were asked to issue a price list to the regulator through the Integrated Drug Database Management System (IPDMS) and submit a copy to the controller and drug dealers. of State.

In a separate notification, the NPPA also announced the price cap for Framycetin, an antibiotic which, in addition to treating burns, is also used to treat bacterial skin infections and skin disorders. Cream (dosed at 0.5%) will have a ceiling price of ₹1.19 per gram.

Published on

April 19, 2022